Featured Research

from universities, journals, and other organizations

Predicting drug responsiveness in cancer patients

Date:
July 26, 2010
Source:
Journal of Clinical Investigation
Summary:
Drugs that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. Now, a team of researchers has identified a way to help predict which patients will respond to such drugs.

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

Specifically, the team found that human cancer cells with mutations in the PIK3CA gene responded to everolimus in vitro except when a KRAS gene mutation was also present. Importantly, in a cohort of metastatic cancer patients, the presence of KRAS gene mutations was associated with lack of response to treatment with everolimus therapy. These data suggest that by looking for the presence or absence of PIK3CA and KRAS mutations in a person's tumor it will be possible to predict whether or not that person will benefit from treatment with a drug that targets mTOR.

However, as noted in an accompanying commentary, by Morassa Mohseni and Ben Ho Park, at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, while these data have enormous potential to change clinical practice, larger prospective studies are required to verify them.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Nicolantonio et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI37539
  2. Morassa Mohseni, Ben Ho Park. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI44026

Cite This Page:

Journal of Clinical Investigation. "Predicting drug responsiveness in cancer patients." ScienceDaily. ScienceDaily, 26 July 2010. <www.sciencedaily.com/releases/2010/07/100726123924.htm>.
Journal of Clinical Investigation. (2010, July 26). Predicting drug responsiveness in cancer patients. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2010/07/100726123924.htm
Journal of Clinical Investigation. "Predicting drug responsiveness in cancer patients." ScienceDaily. www.sciencedaily.com/releases/2010/07/100726123924.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins